Keeping you up to date on recent developments in orthopedics, including: Scientists regenerate neurons in mice with spinal cord injury and optic nerve damage; Trial questions benefits of organic nitrates for bone health; Mind-controlled arm prostheses that 'feel' are now a part of everyday life; Biomaterial immune control discoveries could reduce implant rejection.
Despite a drop off in elective procedures due to the COVID-19 pandemic, Stryker Corp., of Kalamazoo, Mich., unveiled first-quarter results that came in better than analysts had presumed. BTIG’s Ryan Zimmerman noted that, unlike other companies, Stryker did not pre-announce preliminary revenue. And while investors were concerned that the company would be adversely affected by the slump in elective procedures, "the diversity of the portfolio helped to offset procedure declines in late March.”
Carmell Therapeutics Corp., of Pittsburgh, received fast track designation from the U.S. FDA for its first product, CT-101, a bone healing accelerant. Carmell is gearing up for a phase III study of the plasma-based bioactive accelerant as part of its pursuit of a biologic license application.
Carmell Therapeutics Corp., of Pittsburgh, received fast track designation from the U.S. FDA for its first product, CT-101, a bone healing accelerant. Carmell is gearing up for a phase III study of the plasma-based bioactive accelerant as part of its pursuit of a biologic license application.
Keeping you up to date on recent developments in orthopedics, including: Physio support in COVID-19 recovery; Co-delivery of IL-10 and NT-3 to enhance spinal cord injury repair; European countries face a costly 23% increase in fragility fractures by 2030.
Keeping you up to date on recent developments in orthopedics, including: Co-delivery of IL-10 and NT-3 to enhance spinal cord injury repair; Marshall School of Medicine team explores surgery technology resulting in fewer incisions; Researchers discover treatment for spasticity in mice, following spinal cord injuries.
The Trump administration has proposed a policy to gradually reopen the U.S. for business, part of which is to allow a resumption of elective procedures and treatments in outpatient settings. While patients with urgent medical needs presumably are being treated already, the policy would seem to promise a boost in volumes for certain devices, such as coronary artery stents, knee implants and transcatheter aortic valve replacement (TAVR) devices, all of which enjoy at least limited Medicare coverage for outpatient use.
Keeping you up to date on recent developments in orthopedics, including: Researchers develop synthetic scaffolds to heal injured tendons, ligaments; Self-powered X-ray detector to revolutionize imaging for medicine, security and research; Opioid prescriptions linked to obesity.
Keeping you up to date on recent developments in orthopedics, including: Excess weight during pre-school linked to higher bone fracture risk; Cells must age for muscles to regenerate in muscle-degenerating diseases; COVID-19 pandemic may exacerbate childhood obesity.
Warsaw, Ind.-based Orthopediatrics Corp. is scooping up Apifix Ltd., allowing it to gain the Minimally Invasive Deformity Correction (MID-C) system, which is used to treat adolescent idiopathic scoliosis. BTIG’s Ryan Zimmerman noted that the deal has a potential value of $67 million plus potential future revenue milestones. “The initial upfront payment has a ~$37 [million] value, composed of $2 million in cash and ~935k shares of common stock,” he added.
RSS
